Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cosford

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonistDehua Huang, Steve F Poon, Deborah F Chapman, et al.
Analytical Biochemistry|February 28, 2003
Identification of metabotropic glutamate receptor antagonists using an automated high-throughput screening systemPeter Hodder, Jason Cassaday, Richard Peltier, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterizationJeffery J Anderson, Sara P Rao, Blake Rowe, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2005
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonistsLida R Tehrani, Nicholas D Smith, Dehua Huang, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activityNicholas D Smith, Steve F Poon, Dehua Huang, et al.
Cell Death & Disease|October 31, 2014
Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinomaK E McCabe, K Bacos, D Lu, et al.
Chemical Biology & Drug Design|July 28, 2011
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptorsRoberta Noberini, Surya K De, Ziming Zhang, et al.
Frontiers in Pharmacology|March 7, 2017
Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment ProductionKaren S Poksay, Douglas J Sheffler, Patricia Spilman, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 9, 2026
Erratum to "Spontaneous daily sleep disruptions associated with morphine dependence and withdrawal in rats" [The Journal of Pharmacology and Experimental Therapeutics 392 (2025) 103766]Harlie A McKelvey, Bethany E Pierce, Jesse M Lynch, et al.
Journal of Medicinal Chemistry|January 10, 2003
3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activityNicholas D P Cosford, Lida Tehrani, Jeffrey Roppe, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonistDehua Huang, Steve F Poon, Deborah F Chapman, et al.
Analytical Biochemistry|February 28, 2003
Identification of metabotropic glutamate receptor antagonists using an automated high-throughput screening systemPeter Hodder, Jason Cassaday, Richard Peltier, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterizationJeffery J Anderson, Sara P Rao, Blake Rowe, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2005
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonistsLida R Tehrani, Nicholas D Smith, Dehua Huang, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activityNicholas D Smith, Steve F Poon, Dehua Huang, et al.
Cell Death & Disease|October 31, 2014
Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinomaK E McCabe, K Bacos, D Lu, et al.
Chemical Biology & Drug Design|July 28, 2011
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptorsRoberta Noberini, Surya K De, Ziming Zhang, et al.
Frontiers in Pharmacology|March 7, 2017
Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment ProductionKaren S Poksay, Douglas J Sheffler, Patricia Spilman, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 9, 2026
Erratum to "Spontaneous daily sleep disruptions associated with morphine dependence and withdrawal in rats" [The Journal of Pharmacology and Experimental Therapeutics 392 (2025) 103766]Harlie A McKelvey, Bethany E Pierce, Jesse M Lynch, et al.
Journal of Medicinal Chemistry|January 10, 2003
3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activityNicholas D P Cosford, Lida Tehrani, Jeffrey Roppe, et al.
Pageof 11